Opções Terapêuticas Farmacológicas na Acne vulgar

Tomás Esteves Caseiro Mendes de Freitas; Glória Maria Cardoso da Cunha Velho

doi:10.29021/spdv.79.2.1370

Tomás Esteves Caseiro Mendes de Freitas Mestre em Medicina - Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal https://orcid.org/0000-0002-2657-2395
Glória Maria Cardoso da Cunha Velho Assistente Graduada de Dermatologia e Venereologia; Professora Auxiliar Convidada de Dermatologia da Unidade Curricular de Medicina I e Especialidades Médicas do Mestrado Integrado em Medicina no Instituto Ciências Biomédicas Abel Salazar/Centro Hospitalar do Porto, Porto, Portugal https://orcid.org/0000-0001-9242-8976

DOI: https://doi.org/10.29021/spdv.79.2.1370

Palavras-chave: Acne Vulgar/tratamento farmacológico, Administração Cutânea, Administração Oral, Fármacos Dermatológicos

Resumo

A acne vulgar é uma patologia crónica da unidade pilossebácea caracterizada por polimorfismo cutâneo, sendo das mais prevalentes na adolescência. Pode originar sequelas físicas, como cicatrizes desfigurantes, e psicológicas, nomeadamente diminuição da qualidade de vida e função psicossocial. Assim, torna-se fundamental uma estratégia terapêutica eficaz de modo a promover a sua resolução e, simultaneamente, minimizar a presença destas sequelas. Atualmente, os fármacos disponíveis são diversos, obrigando, na sua seleção, à avaliação biopsicossocial do doente. Estudos recentes têm apontado novos agentes terapêuticos promissores, nomeadamente alternativas aos retinóides tópicos, isotretinoína oral, antiandrogénios orais e antibióticos. Estes poderão permitir uma redução da resistência antibiótica e consequente aumento da eficácia com redução substancial dos efeitos adversos. O melhor perfil de segurança e tolerabilidade poderá otimizar a abordagem terapêutica atual.

Downloads

Não há dados estatísticos.

Referências

Amer SS, Nasr M, Mamdouh W, Sammour O. Insights on the use of nanocarriers for acne alleviation. Curr Drug Deliv. 2019;16:18-25.

Becker M, Wild T, Zouboulis CC. Objective assessment of acne. Clin Dermatol. 2017;35:147–55.

Williams H C, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379: 361–72.

Kontochristopoulos G, Platsidaki E. Chemical peels in active acne and acne scars. Clin Dermatol. 2017;35:179–82.

Wolkenstein P, Machovcová A, Szepietowski JC, Tennstedt D, Veraldi S, Delarue A. Acne prevalence and associations with lifestyle: a cross-sectional online survey of adolescents/young adults in 7 European countries. J Eur Acad Dermatol Venereol. 2017;32:298–306.

Barnes LE, Levender MM, Fleischer AB, Feldman SR. Quality of Life Measures for Acne Patients. Dermatol Clin. 2012;30:293–300.

Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74:945–73.

Gieler U, Gieler T, Kupfer J. Acne and quality of life - impact and management. J Eur Acad Dermatol Venereol. 2015;29:12–4.

Revol O, Milliez N, Gerard D. Psychological impact of acne on 21st-century adolescents: decoding for better care. Br J Dermatol. 2015;172:52–8.

Jankovic S, Vukicevic J, Djordjevic S, Jankovic J, Marinkovic J, et al. Quality of life among schoolchildren with acne: Results of a cross-sectional study. Indian J Dermatol Venereol Leprol. 2012;78:454.

Tuchayi SM, Makrantonaki E, Ganceviciene R, Dessinioti C, Feldman SR, Zouboulis CC. Acne vulgaris. Nat Rev Dis Primers. 2015;15033.

Läuchli S. Acne Vulgaris. Curr Probl Dermatol. 2011;42:140–6.

Knutsen-Larson S, Dawson AL, Dunnick CA, Dellavalle RP. Acne Vulgaris: Pathogenesis, Treatment, and Needs Assessment. Dermatol Clin. 2012;30: 99–106.

Trivedi MK, Bosanac SS, Sivamani RK, Larsen LN. Emerging therapies for acne vulgaris. Am J Clin Dermatol. 2018;19:505–16.

Well D. Acne vulgaris. Nurse Pract. 2013;38:22–31.

Botros PA, Tsai G, Pujalte GG. Evaluation and management of acne. Prim Care. 2015;42, 465–471.

Kim RH, Armstrong AW. Current state of acne treatment: highlighting lasers, photodynamic therapy, and chemical peels. Dermatol Online J. 2011;17(3):2.

Das S, Reynolds RV. Recent advances in acne pathogenesis: implications for therapy. Am J Clin Dermatol. 2014;15: 479–88.

Dréno B. What is new in the pathophysiology of acne, an overview. J Eur Acad Dermatol Venereol. 2017;31: 8–12.

Dréno B, Gollnick HP, Kang S, Thiboutot D, Bettoli V, Torres V, et al. Understanding innate immunity and inflammation in acne: implications for management. J Eur Acad Dermatol Venereol. 2015;29: 3–11.

Suh DH, Kwon HH. What’s new in the physiopathology of acne? Br J Dermatol. 2015;172:13–9.

Smith EV, Grindlay DJ, Williams HC. What’s new in acne? An analysis of systematic reviews published in 2009-2010. Clin Exp Dermatol. 2011;36:119–22.

Taylor M, Gonzalez M, Porter R. Pathways to inflammation: acne pathophysiology. Eur J Dermatol. 2011;21: 323-33

Dréno B, Bettoli V, Araviiskaia E, Viera MS, Bouloc A. The influence of exposome on acne. J Eur Acad Dermatol Venereol. 2018;32:812–9.

Gollnick HP. From new findings in acne pathogenesis to new approaches in treatment. J Eur Acad Dermatol Venereol. 2015;29:1–7.

Goh CL, Abad-Casintahan F, Aw DC, Baba R, Chan LC, Hung NT et al. South-East Asia study alliance guidelines on the management of acne vulgaris in South-East Asian patients. J Dermatol. 2015;42:945–53.

Gollnick HP, Bettoli V, Lambert J, Araviiskaia E, Binic I, Dessinioti C, et al. A consensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol. 2016;30:1480–90.

Kosmadaki M, Katsambas A. Topical treatments for acne. Clin Dermatol. 2017;35:173–8.

Simonart T. Newer approaches to the treatment of acne vulgaris. Am J Clin Dermatol. 2012;13:357–64.

Kolli SS, Pecone D, Pona A, Cline A, Feldman SR. Topical retinoids in acne vulgaris: a systematic review. Am J Clin Dermatol. 2019;20:345-65.

Imahiyerobo-Ip JI, Dinulos JG. Changing the topography of acne with topical medications. Curr Opin Pediatr. 2011;23:121–5.

Veraldi S, Barbareschi M, Benardon S, Schianchi R. Short contact therapy of acne with tretinoin. J Dermatolog Treat. 2013;24:374–6.

Hsu P, Litman GI, Brodell RT. Overview of the treatment of acne vulgaris with topical retinoids. Postgrad Med. 2011;123:153-61.

Leyden J. Recent advances in the use of adapalene 0.1%/benzoyl peroxide 2.5% to treat patients with moderate to severe acne. J Dermatolog Treat. 2016;27: S4–S13.

Gonzalez P, Vila R, Cirigliano M. The tolerability profile of clindamycin 1%/benzoyl peroxide 5% gel vs. adapalene 0.1%/benzoyl peroxide 2.5% gel for facial acne: results of a randomized, single-blind, split-face study. J Cosmet Dermatol. 2012;11:251–60.

Maiti R, Sirka CS, Ashique Rahman MA, Srinivasan A, Parida S, Hota D. Efficacy and Safety of Tazarotene 0.1% Plus Clindamycin 1% Gel Versus Adapalene 0.1% Plus Clindamycin 1% Gel in Facial Acne Vulgaris: A Randomized, Controlled Clinical Trial. Clin Drug Investig. 2017;37:1083–91.

Smith JA, Narahari S, Hill D, Feldman SR. Tazarotene foam, 0.1%, for the treatment of acne. Exp Opin Drug Saf. 2015;15:99–103.

Ahluwalia J, Borok J, Haddock ES, Ahluwalia RS., Schwartz EW, Hosseini D, et al. The microbiome in preadolescent acne: Assessment and prospective analysis of the influence of benzoyl peroxide. Pediatr Dermatol. 2019;36:200-6.

Kawashima M, Nagare T, Doi M. Clinical efficacy and safety of benzoyl peroxide for acne vulgaris: Comparison between Japanese and Western patients. J Dermatol. 2016;44:1212–18.

Gold LS, Weiss J, Rueda MJ, Liu H, Tanghetti E. Moderate and severe inflammatory acne vulgaris effectively treated with single-agent therapy by a new fixed-dose combination adapalene 0.3 %/ benzoyl peroxide 2.5 % gel: a randomized, double-blind, parallel-group, controlled study. Am J Clin Dermatol. 2016;17:293–303.

Draelos ZD, Ertel K, Rom D. Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. J Cosmet Dermatol. 2016;15:350–7.

Gamble R, Dunn J, Dawson A, Petersen B, McLaughling L, Small A, et al. Topical Antimicrobial Treatment of Acne Vulgaris. Am J Clin Dermatol. 2012;13:141–52.

Valente Duarte de Sousa IC. Novel pharmacological approaches for the treatment of acne vulgaris. Expert Opin Investig Drugs. 2014;23:1389–410.

Sieber MA, Hegel JK. Azelaic Acid: Properties and Mode of Action. Skin Pharmacol Physiol. 2014;27: 9–17.

Pazoki-Toroudi H, Nilforoushzadeh MA, Ajami M, Jaffary F, Aboutaleb N, Nassiri-Kashani M et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutan Ocul Toxicol. 2011;30:286–91.

Leccia MT, Auffret N, Poli F, Claudel JP, Corvec S, Dreno B. Topical acne treatments in Europe and the issue of antimicrobial resistance. J Eur Acad Dermatol Venereol. 2015;29:1485–92.

Fox L, Csongrad C, Aucamp M, Du Plessis J, Gerber M. Treatment Modalities for Acne. Molecules. 2016;21:1063. doi: 10.3390/molecules21081063.

Keating GM. Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel. Am J Clin Dermatol. 2011;12: 407–20.

Gollnick H, Abanmi AA, Al-Enezi M, Al Hammadi A, Galadari I, Kibbi AG, et al. Managing acne in the Middle East: consensus recommendations. J Eur Acad Dermatol Venereol. 2017;31:4–35.

Eichenfield LF, Fowler JF, Fried RG, Friedlander SF, Levy ML, Webster GF. Perspectives on therapeutic options for acne: an update. Semin Cutan Med Surg. 2010;29: 13–16.

Newman, MD, Bowe, WP, Heughebaert C, Shalita AR. Therapeutic Considerations for Severe Nodular Acne. Am J Clin Dermatol. 2011;12:7–14.

Farrah G, Tan E. The use of oral antibiotics in treating acne vulgaris: a new approach. Dermatol Ther. 2016;29:377–84.

Bagatin E, Florez-White M, Arias-Gomez, M. I., Kaminsky A. Algorithm for acne treatment: Ibero-Latin American consensus. An Bras Dermatol. 2017;92:689–93.

Bienenfeld A, Nagler AR, Orlow SJ. Oral antibacterial therapy for acne vulgaris: an evidence-based review. Am J Clin Dermatol. 2017;18:469–90.

Dessinioti C, Katsambas A. Propionibacterium acnes and antimicrobial resistance in acne. Clin Dermatol. 2017;35:163–7.

Dumont-Wallon G, Moyse D, Blouin E, Dréno B. Bacterial resistance in French acne patients. Int J Dermatol. 2010;49:283–8.

On SC, Zeichner J. Isotretinoin updates. Dermatol Ther. 2013;26:377–89.

Rademaker M. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Australas J Dermatol. 2012;54:157–62.

Sandoval LF, Hartel JK, Feldman SR. Current and future evidence-based acne treatment: a review. Expert Opin Pharmacother. 2013;15:173–92.

Nast A, Dréno B, Bettoli V, Degitz K, Erdmann R, Finlay AY, et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012;1:1-29.

Bauer LB, Ornelas JN, Elston DM, Alikhan A. Isotretinoin: controversies, facts, and recommendations. Expert Rev Clin Pharmacol. 2016;9:1435–42.

Brzezinski P, Borowska K, Chiriac A, Smigielski J. Adverse effects of isotretinoin: A large, retrospective review. Dermatol Ther. 2017;30:e12483.

Aslam I, Fleischer A, Feldman S. Emerging drugs for the treatment of acne. Expert Opin Emerg Drugs. 2014;20:91–101.

Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first line therapy? facts and controversies. Clin Dermatol. 2010;28:17–23.

Tripathi SV, Gustafson CJ, Huang KE, Feldman SR. Side effects of common acne treatments. Expert Opin Drug Saf. 2012;12:39–51.

Husein-ElAhmed H. Management of acne vulgaris with hormonal therapies in adult female patients. Dermatol Ther. 2015;28:166–72.

Barros B, Thiboutot D. Hormonal therapies for acne. Clin Dermatol. 2017;35(2), 168–172.

Mwanthi M, Zaenglein AL. Update in the management of acne in adolescence. Curr Opin Pediatr. 2018;30:492-8.

Lakshmi C. Hormone therapy in acne. Indian J Dermatol Venereol Leprol. 2013;79:322.

Nguyen HL, Tollefson MM. Endocrine disorders and hormonal therapy for adolescent acne. Curr Opin Pediatr. 2017;29:455–65.

Bettoli V, Zauli S, Virgili A. Is hormonal treatment still an option in acne today? Br J Dermatol. 2015;172:37–46.

Bissonnette R, Poulin Y, Drew J, Hofland H, Tan J. Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study. J Am Acad Dermatol. 2017;76:33–9.